low molecular weight heparin

A low molecular weight heparin, molecular weight technology, applied in the field of low molecular weight heparin, can solve problems such as lack of treatment methods

Active Publication Date: 2020-09-04
BEIJING BICHENG BIOTECH CO LTD
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there are many patients with fibrotic diseases, the research on the molecular mechanism involved is preliminary, and there is a lack of effective treatment methods

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • low molecular weight heparin
  • low molecular weight heparin
  • low molecular weight heparin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0070] Example 1 Preparation of low molecular weight heparin 1 (hereinafter, also referred to as low molecular weight heparin I-11)

[0071] Combine 5g heparin (purchased from Changshan Biochemical Pharmaceutical Co., Ltd., product name: heparin sodium, with a molecular weight distribution of 5,000 to 30,000, with an average molecular weight of 20,000) and 100 mL Tris buffer (20mM Tris, 50mM NaCl, 20mM CaCl) 2 ) Mix and prepare a 50 g / L heparin solution (pH 7.6), and add heparinase I prepared according to ZL200410038098.6 with a total enzyme activity of 100 IU to 100 mL of the prepared 50 g / L heparin solution. Use a quartz cuvette with an optical path difference of 1 cm and an ultraviolet spectrophotometer to monitor the solution's light absorption A231 at 231 nm. When A231 reaches the reaction control point (A231=46.3), the reaction is completed. The method of ending is to inactivate the enzyme in the reaction solution in a boiling water bath at 100°C for 5-10 minutes, and then t...

Embodiment 2

[0076] Example 2 Preparation of low molecular weight heparin 2 (hereinafter, also referred to as low molecular weight heparin III-II-5)

[0077] To 100mL of 50g / L heparin solution prepared in the same way as in Example 1, an excess of heparinase III (215IU) prepared in accordance with ZL201010259913.7 was added to the end of the reaction, and ultraviolet absorption spectroscopy (A231) was used to determine the heparinase reaction. End point (control at A231=20), and then add heparinase II (20IU) prepared according to the ZL201010259905.2 method, and when A231 reaches the reaction control point (A231=61), the reaction is ended. The method to end is to take a certain volume of the reaction solution (300ml), inactivate it in a boiling water bath at 100°C for 5-10 minutes, cool to room temperature, add 6 times the volume of absolute ethanol, stir at room temperature for 10 minutes, stir for 10 minutes, and then at room temperature Centrifuge at 4000r / min for 15min, collect the precip...

Embodiment 3

[0079] Example 3 Preparation of low molecular weight heparin 3 (hereinafter, also referred to as low molecular weight heparin II-11)

[0080] To 100 mL of a 50g / L heparin solution prepared in the same way as in Example 1, heparinase II prepared according to ZL201010259905.2 with a total enzyme activity of 100 IU was added at one time. Use a quartz cuvette with an optical path difference of 1 cm and an ultraviolet spectrophotometer to monitor the solution's light absorption A231 at 231 nm. When A231 reaches the reaction control point (A231=46.5), the reaction is completed. The method of ending is to inactivate the enzyme in the reaction solution in a boiling water bath at 100°C for 5-10 minutes, and then take out the reaction system and cool it to room temperature. Add 6 times the volume of absolute ethanol, stir at room temperature for 10 minutes, then centrifuge at 4000r / min for 15 minutes at room temperature, collect the precipitate, add deionized water 2 to 3 times the mass of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
number average molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention relates to low molecular weight heparin used for treating and / or preventing liver fibrosis. For the low molecular weight heparin, the range of number-average molecular weight (Mn) is 2800-5000Da, the range of weight-average molecular weight (Mw) is 6100-13000Da, the range of optimal number-average molecular weight (Mn) is 3000-4500Da, the range of weight-average molecular weight (Mw)is 6200-12000Da, further, the range of optimal number-average molecular weight (Mn) is 3200-4400Da, the range of weight-average molecular weight (Mw) is 6300-11000Da, further, the range of optimal number-average molecular weight (Mn) is 3250-4200Da, and the range of weight-average molecular weight (Mw) is 6400-10500Da.

Description

Technical field [0001] The invention relates to a new low-molecular-weight heparin and its use for preparing medicines for preventing or treating liver fibrosis. Background technique [0002] Fibrosis disease is the accumulation of collagen-rich extracellular matrix (ECM) in the tissues and organs due to abnormal and excessive repair of tissues after continuous damage, causing the parenchymal cells to lose their original functions. Fibrotic diseases include diseases involving multiple systems, such as systemic sclerosis, multifocal fibrosis, scleroderma, and nephrogenic multisystem fibrosis. It also includes organ-specific diseases, such as lung, liver, and kidney fibrosis. [0003] Because different fibrotic lesions involve different organs and tissues, are exposed to different environmental factors, and are composed of different cell types, but the fibrosis process has a similar pathological process: epithelial cells are continuously damaged and excessive cytokines are secreted ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C08B37/10C12P19/04A61K31/727A61P1/16
CPCA61K31/727C08B37/0078C12P19/04
Inventor 苏楠闫轶姝毕鲜荣
Owner BEIJING BICHENG BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products